At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Recombinant Lactoferrin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
In Brief
A Phase 2 clinical trial evaluating Recombinant Lactoferrin and Placebo for HIV Infection. Completed, enrolled 55 participants across 1 site.
Detailed Summary
Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesUnited States
CollaboratorsVentria Bioscience
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartSep 2014
Primary CompletionJul 2017
Study CompletionJan 2018
TodayJul 2026
First PostedApr 12, 2013
Enrollment StartSep 1, 2014
Primary CompletionJul 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.2 years ago
Interventions
Recombinant Lactoferrindrug
Placebodrug